Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Wheeler, Heather E ^a   Gorsic, Lidija K ^a   Welsh, Marleen ^a,b   Stark, Amy L ^a   Gamazon, Eric R ^a   Cox, Nancy J ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; DOXIFLURIDINE; ANTINEOPLASTIC AGENT;

AFRICAN AMERICAN; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CONTROLLED STUDY; COPS5 GENE; DRUG CYTOTOXICITY; GAS8 GENE; GENE ACTIVITY; GENE DOSAGE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; ONCOGENE; PLESIOMORPHY; POPULATION STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM; TP53L11 GENE; CELL DEATH; CELL LINE; CHILD; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE; GENEALOGY; GENETICS; HUMAN GENOME; MALE; PHENOTYPE; UNITED STATES;

AFRICAN AMERICANS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL DEATH; CELL LINE; CHILD; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENEALOGY AND HERALDRY; GENES; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SOUTHWESTERN UNITED STATES;

EID: 79960026939     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021920     Document Type: Article

References (67)

1. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106: 9362-9367.
2. Rotimi CN, Jorde LB, (2010) Ancestry and disease in the age of genomic medicine. N Engl J Med 363: 1551-1558.
3. Need AC, Goldstein DB, (2009) Next generation disparities in human genomics: concerns and remedies. Trends Genet 25: 489-494.
4. Kang SJ, Chiang CW, Palmer CD, Tayo BO, Lettre G, et al. (2010) Genome-wide association of anthropometric traits in African- and African-derived populations. Hum Mol Genet 19: 2725-2738.
5. Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, et al. (2009) Pharmacogenomic discovery using cell-based models. Pharmacol Rev 61: 413-429.
6. Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, et al. (2009) Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113: 2145-2153.
7. Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME, (2008) Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther 7: 3038-3046.
8. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, et al. (2007) Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 81: 427-437.
9. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, et al. (2009) Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 4: e7765.
10. Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL, (2004) Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A 101: 11809-11814.
11. Choy E, Yelensky R, Bonakdar S, Plenge RM, Saxena R, et al. (2008) Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet 4: e1000287.
12. Stark AL, Zhang W, Mi S, Duan S, O'Donnell PH, et al. (2010) Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J.
13. Niu N, Schaid DJ, Fridley BL, Kalari K, Li L, et al. (2011) Oral Session III-B (OIII-B) Molecular Targets and Genetics in Oncology 9:30 am- 10:30 am. Clin Pharmacol Ther 89: S66-S68.
14. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, et al. (2011) Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res 157: 265-272.
15. Baker WJ, Royer GL Jr, Weiss RB, (1991) Cytarabine and neurologic toxicity. J Clin Oncol 9: 679-693.
16. Briasoulis E, Pavlidis N, (2001) Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist 6: 153-161.
17. Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, et al. (2002) In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 117: 860-868.
18. Reykdal S, Sham R, Kouides P, (1995) Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res 19: 141-144.
19. Styczynski J, (2007) Drug resistance in childhood acute myeloid leukemia. Curr Pharm Biotechnol 8: 59-75.
20. Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, et al. (2006) Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood 108: 74-80.
21. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P, (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98: 610-615.
22. McMurrough J, McLeod HL, (1996) Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 41: 425-427.
23. Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, et al. (2010) African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer.
24. Polite BN, Dignam JJ, Olopade OI, (2006) Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol 24: 2179-2187.
25. Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, et al. (2008) Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol 3: 1286-1292.
26. McWhinney SR, Goldberg RM, McLeod HL, (2009) Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8: 10-16.
27. Micheletti E, La Face B, Bianchi E, Cagna E, Apostoli P, et al. (1997) Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB-IIIB (UICC). A phase I/II and pharmacokinetic study. Am J Clin Oncol 20: 613-620.
28. Siddik ZH, (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
29. Wang D, Lippard SJ, (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320.
30. Rabik CA, Dolan ME, (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23.
31. Celik I, Kars A, Ozyar E, Tekuzman G, Atahan L, et al. (1996) Major toxicity of cisplatin, fluorouracil, and leucovorin following chemoradiotherapy in patients with nasopharyngeal carcinoma. J Clin Oncol 14: 1043-1044.
32. van Glabbeke M, Renard J, Pinedo HM, Cavalli F, Vermorken J, et al. (1988) Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG). Eur J Cancer Clin Oncol 24: 255-262.
33. ACS, (2005) Cancer facts & figures for African Americans 2005-2006. American Cancer Society.
34. Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, et al. (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467: 52-58.
35. Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, et al. (2010) A versatile gene-based test for genome-wide association studies. Am J Hum Genet 87: 139-145.
36. Bryc K, Auton A, Nelson MR, Oksenberg JR, Hauser SL, et al. (2010) Genome-wide patterns of population structure and admixture in West Africans and African Americans. Proc Natl Acad Sci U S A 107: 786-791.
37. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904-909.
38. Price AL, Tandon A, Patterson N, Barnes KC, Rafaels N, et al. (2009) Sensitive detection of chromosomal segments of distinct ancestry in admixed populations. PLoS Genet 5: e1000519.
39. Gamazon ER, Huang RS, Cox NJ, Dolan ME, (2010) Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A 107: 9287-9292.
40. Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, et al. (2008) Genetic architecture of transcript-level variation in humans. Am J Hum Genet 82: 1101-1113.
41. Tian L, Peng G, Parant JM, Leventaki V, Drakos E, et al. (2010) Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 29: 6125-6137.
42. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, et al. (2001) Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res 7: 4130-4135.
43. Rassidakis GZ, Claret FX, Lai R, Zhang Q, Sarris AH, et al. (2003) Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin Cancer Res 9: 1121-1128.
44. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, et al. (2003) Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 63: 2977-2981.
45. Harada K, Kawashima Y, Yoshida H, Sato M, (2006) High expression of Jun activation domain-binding protein 1 (Jab1) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation. Anticancer Res 26: 1615-1619.
46. Dong Y, Sui L, Watanabe Y, Yamaguchi F, Hatano N, et al. (2005) Prognostic significance of Jab1 expression in laryngeal squamous cell carcinomas. Clin Cancer Res 11: 259-266.
47. Wu Y, Liu XM, Wang XJ, Zhang Y, Liang XQ, et al. (2009) PIG11 is involved in hepatocellular carcinogenesis and its over-expression promotes Hepg2 cell apoptosis. Pathol Oncol Res 15: 411-416.
48. Shain SA, (2004) Exogenous fibroblast growth factors maintain viability, promote proliferation, and suppress GADD45alpha and GAS6 transcript content of prostate cancer cells genetically modified to lack endogenous FGF-2. Mol Cancer Res 2: 653-661.
49. Whitmore SA, Settasatian C, Crawford J, Lower KM, McCallum B, et al. (1998) Characterization and screening for mutations of the growth arrest-specific 11 (GAS11) and C16orf3 genes at 16q24.3 in breast cancer. Genomics 52: 325-331.
50. Adeyemo A, Gerry N, Chen G, Herbert A, Doumatey A, et al. (2009) A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet 5: e1000564.
51. Deo RC, Reich D, Tandon A, Akylbekova E, Patterson N, et al. (2009) Genetic differences between the determinants of lipid profile phenotypes in African and European Americans: the Jackson Heart Study. PLoS Genet 5: e1000342.
52. Bonilla C, Hooker S, Mason T, Bock CH, Kittles RA, (2011) Prostate cancer susceptibility Loci identified on chromosome 12 in african americans. PLoS One 6: e16044.
53. Pasaniuc B, Zaitlen N, Lettre G, Chen GK, Tandon A, et al. (2011) Enhanced Statistical Tests for GWAS in Admixed Populations: Assessment using African Americans from CARe and a Breast Cancer Consortium. PLoS Genet 7: e1001371.
54. Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, et al. (2004) Methods for high-density admixture mapping of disease genes. Am J Hum Genet 74: 979-1000.
55. Sankararaman S, Sridhar S, Kimmel G, Halperin E, (2008) Estimating local ancestry in admixed populations. Am J Hum Genet 82: 290-303.
56. Sundquist A, Fratkin E, Do CB, Batzoglou S, (2008) Effect of genetic divergence in identifying ancestral origin using HAPAA. Genome Res 18: 676-682.
57. Hao K, Chudin E, McElwee J, Schadt EE, (2009) Accuracy of genome-wide imputation of untyped markers and impacts on statistical power for association studies. BMC Genet 10: 27.
58. Jallow M, Teo YY, Small KS, Rockett KA, Deloukas P, et al. (2009) Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet 41: 657-665.
59. Durbin RM, Abecasis GR, Altshuler DL, Auton A, The 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061-1073.
60. Kaiser J, (2008) DNA sequencing. A plan to capture human diversity in 1000 genomes. Science 319: 395.
61. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, et al. (2007) Population genomics of human gene expression. Nat Genet 39: 1217-1224.
62. Schadt EE, Molony C, Chudin E, Hao K, Yang X, et al. (2008) Mapping the genetic architecture of gene expression in human liver. PLoS Biol 6: e107.
63. Stark AL, Zhang W, Zhou T, O'Donnell PH, Beiswanger CM, et al. (2010) Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet 87: 829-833.
64. Browning BL, Browning SR, (2009) A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet 84: 210-223.
65. Abecasis GR, Cookson WO, Cardon LR, (2000) Pedigree tests of transmission disequilibrium. Eur J Hum Genet 8: 545-551.
66. Devlin B, Roeder K, (1999) Genomic control for association studies. Biometrics 55: 997-1004.
67. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, et al. (2010) LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26: 2336-2337.